{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:19:45Z","timestamp":1790709585701,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10575-2","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:14:55Z","timestamp":1764645295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacological prevention in cardio-oncology: from bench-to-bedside"],"prefix":"10.1007","volume":"31","author":[{"given":"Ashot A.","family":"Avagimyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Pogosova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Urazova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Djndoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliya","family":"Mirzoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayane","family":"Avetisyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Spadafora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Perone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Biondi","family":"Zoccai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Asteggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizal","family":"Sarrafzadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"1","key":"10575_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10575_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101227","volume":"48","author":"S Shi","year":"2023","unstructured":"Shi S, Lv J, Chai R et al (2023) Opportunities and challenges in cardio-oncology: a bibliometric analysis from 2010 to 2022. Curr Probl Cardiol 48(8):101227. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101227","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"10575_CR3","doi-asserted-by":"publisher","first-page":"101435","DOI":"10.1016\/j.cpcardiol.2022.101435","volume":"48","author":"T Ahmed","year":"2023","unstructured":"Ahmed T, Marmagkiolis K, Ploch M et al (2023) Year in Cardio-oncology 2022. Curr Probl Cardiol 48(1):101435. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101435","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"10575_CR4","doi-asserted-by":"publisher","first-page":"102951","DOI":"10.1016\/j.cpcardiol.2024.102951","volume":"50","author":"N An","year":"2025","unstructured":"An N, Zhang X, Lin H et al (2025) Role and mechanism of TXNDC5 in cardio-oncology: killing two birds with one stone? Curr Probl Cardiol 50(3):102951. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102951","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"10575_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102389","volume":"49","author":"S Imran","year":"2024","unstructured":"Imran S, Rao MS, Shah MH et al (2024) Evolving perspectives in reverse cardio-oncology: A review of current status, pathophysiological insights, and future directives. Curr Probl Cardiol 49(3):102389. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102389","journal-title":"Curr Probl Cardiol"},{"issue":"4","key":"10575_CR6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V et al (2025) Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 31(4):1154\u20131162. https:\/\/doi.org\/10.1038\/s41591-025-03502-3","journal-title":"Nat Med"},{"issue":"17","key":"10575_CR7","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH et al (2023) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 118(17):3272\u20133287. https:\/\/doi.org\/10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"10575_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/2404806","volume":"2023","author":"F Masoudkabir","year":"2023","unstructured":"Masoudkabir F, Mohammadifard N, Mani A et al (2023) Shared lifestyle-related risk factors of cardiovascular disease and cancer: evidence for joint prevention. Sci World J 2023:2404806. https:\/\/doi.org\/10.1155\/2023\/2404806","journal-title":"Sci World J"},{"key":"10575_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.atherosclerosis.2017.06.001","volume":"263","author":"F Masoudkabir","year":"2017","unstructured":"Masoudkabir F, Sarrafzadegan N, Gotay C et al (2017) Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis 263:343\u2013351. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.06.001","journal-title":"Atherosclerosis"},{"issue":"2","key":"10575_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.17116\/onkolog20198021139","volume":"8","author":"AD Kaprin","year":"2019","unstructured":"Kaprin AD, Matskeplishvili ST, Potievskaya VI et al (2019) Cardiovascular diseases in cancer patients. Onkologiya. Zhurnal imeni P.A.Gertsena 8(2):139\u2013147. https:\/\/doi.org\/10.17116\/onkolog20198021139","journal-title":"Onkologiya. Zhurnal imeni P.A.Gertsena"},{"issue":"2","key":"10575_CR11","first-page":"132","volume":"78","author":"YI Buziashvili","year":"2023","unstructured":"Buziashvili YI, Stilidi IS, Matskeplishvili ST et al (2023) Cardiovascular and oncological diseases \u2014 focus on modifiable risk factors and modern pathogenetic aspects. Ann Russ Acad Med Sci 78(2):132\u2013140","journal-title":"Ann Russ Acad Med Sci"},{"issue":"9","key":"10575_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41569-024-01017-x","volume":"21","author":"NS Wilcox","year":"2024","unstructured":"Wilcox NS, Amit U, Reibel JB et al (2024) Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol 21(9):617\u2013631. https:\/\/doi.org\/10.1038\/s41569-024-01017-x","journal-title":"Nat Rev Cardiol"},{"issue":"18","key":"10575_CR13","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","volume":"41","author":"J L\u00f3pez-Send\u00f3n","year":"2020","unstructured":"L\u00f3pez-Send\u00f3n J, \u00c1lvarez-Ortega C, Zamora Au\u00f1on P et al (2020) Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 41(18):1720\u20131729. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa006","journal-title":"Eur Heart J"},{"issue":"7","key":"10575_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2025.103039","volume":"50","author":"CO Fischer-Bacca","year":"2025","unstructured":"Fischer-Bacca CO, Huntermann R, de Oliveira JP et al (2025) Systematic review and meta-analysis of right ventricular changes in cancer therapy - the forgotten ventricle in cardio-oncology. Curr Probl Cardiol 50(7):103039. https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103039","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"10575_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.20538\/1682-0363-2024-3-5-15","volume":"23","author":"EN Berezikova","year":"2024","unstructured":"Berezikova EN, Shilov SN, Popova AA et al (2024) Arterial hypertension during breast cancer chemotherapy with anthracyclines. Bull Sib Med 23(3):5\u201315. https:\/\/doi.org\/10.20538\/1682-0363-2024-3-5-15","journal-title":"Bull Sib Med"},{"key":"10575_CR16","doi-asserted-by":"publisher","unstructured":"Akbalaeva BA, Shulzhenko LV, Pershukov IV et al (2024) Speckle-Tracking echocardiography in assessment of breast cancer Therapy-Related subclinical cardiac dysfunction. Innov Med Kuban 28\u201315. https:\/\/doi.org\/10.35401\/2541-9897-2024-9-2-8-15","DOI":"10.35401\/2541-9897-2024-9-2-8-15"},{"issue":"41","key":"10575_CR17","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"10575_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.35401\/2541-9897-2024-9-1-37-44","volume":"1","author":"SG Kanorskiy","year":"2024","unstructured":"Kanorskiy SG, Pavlovets VP (2024) Long-term effects of sacubitril\/valsartan after chemotherapy for breast cancer in patients with chronic heart failure. Innov Med Kuban 1:37\u201344. https:\/\/doi.org\/10.35401\/2541-9897-2024-9-1-37-44","journal-title":"Innov Med Kuban"},{"issue":"4","key":"10575_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.20538\/1682-0363-2022-4-44-53","volume":"21","author":"EV Grakova","year":"2022","unstructured":"Grakova EV, Kopeva KV, Shilov SN et al (2022) Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases. Bull Sib Med 21(4):44\u201353. https:\/\/doi.org\/10.20538\/1682-0363-2022-4-44-53","journal-title":"Bull Sib Med"},{"issue":"5","key":"10575_CR20","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.15829\/1560-4071-2023-5452","volume":"28","author":"SA Boytsov","year":"2023","unstructured":"Boytsov SA, Pogosova NV, Ansheles AA et al (2023) Cardiovascular prevention. 2022. Russian national guidelines. Russ J Cardiol 28(5):5452. https:\/\/doi.org\/10.15829\/1560-4071-2023-5452","journal-title":"Russ J Cardiol"},{"issue":"3","key":"10575_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","volume":"4","author":"C Porter","year":"2022","unstructured":"Porter C, Azam TU, Mohananey D et al (2022) Permissive cardiotoxicity: the clinical crucible of Cardio-Oncology. JACC CardioOncol 4(3):302\u2013312. https:\/\/doi.org\/10.1016\/j.jaccao.2022.07.005","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10575_CR22","doi-asserted-by":"publisher","DOI":"10.36660\/abcimg.20240115i","volume":"38","author":"CMPDC Silva","year":"2025","unstructured":"Silva CMPDC, Seabra-Garcez JD, Neves APL et al (2025) Permissive cardiotoxicity: when the optimal is the enemy of the good. ABC Imagem Cardiovasc 38(1):e20240115. https:\/\/doi.org\/10.36660\/abcimg.20240115i","journal-title":"ABC Imagem Cardiovasc"},{"issue":"1","key":"10575_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0632","volume":"86","author":"J Tong","year":"2025","unstructured":"Tong J, Senechal I, Ramalingam S et al (2025) Risk assessment prior to cardiotoxic anticancer therapy in seven steps. Br J Hosp Med 86(1):1\u201321. https:\/\/doi.org\/10.12968\/hmed.2024.0632","journal-title":"Br J Hosp Med"},{"key":"10575_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ijcard.2021.11.059","volume":"349","author":"G Tini","year":"2022","unstructured":"Tini G, Cuomo A, Battistoni A et al (2022) Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA\/ICOS risk tool in real-world practice. Int J Cardiol 349:134\u2013137. https:\/\/doi.org\/10.1016\/j.ijcard.2021.11.059","journal-title":"Int J Cardiol"},{"issue":"5","key":"10575_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.20996\/1819-6446-2021-10-17","volume":"17","author":"AA Avagimyan","year":"2021","unstructured":"Avagimyan AA, Mkrtchyan LH, Gevorkyan AA et al (2021) Relationship between chemotherapy and atrial fibrillation: clinical case. Ration Pharmacother Cardiol 17(5):785\u2013791. https:\/\/doi.org\/10.20996\/1819-6446-2021-10-17","journal-title":"Ration Pharmacother Cardiol"},{"issue":"29","key":"10575_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf100","volume":"46","author":"SC Adams","year":"2025","unstructured":"Adams SC, Rivera-Theurel F, Scott JM et al (2025) Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group. Eur Heart J ehaf100. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf100","journal-title":"Eur Heart J"},{"issue":"9","key":"10575_CR27","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.15829\/1560-4071-2021-4703","volume":"26","author":"YA Vasyuk","year":"2021","unstructured":"Vasyuk YA, Gendlin GE, Emelina EI et al (2021) \u0421onsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russ J Cardiol 26(9):4703. https:\/\/doi.org\/10.15829\/1560-4071-2021-4703","journal-title":"Russ J Cardiol"},{"issue":"2","key":"10575_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","volume":"31","author":"MW Bloom","year":"2025","unstructured":"Bloom MW, Vo JB, Rodgers JE et al (2025) Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America. J Card Fail 31(2):415\u2013455. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.045","journal-title":"J Card Fail"},{"issue":"5","key":"10575_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.36660\/abc.20201006","volume":"115","author":"LA Hajjar","year":"2020","unstructured":"Hajjar LA, Costa IBSDSSD, Lopes MACQ et al (2020) Brazilian Cardio-Oncology guideline 2020. Arq Bras Cardiol 115(5):1006\u20131043. https:\/\/doi.org\/10.36660\/abc.20201006","journal-title":"Arq Bras Cardiol"},{"issue":"7","key":"10575_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cjca.2016.02.078","volume":"32","author":"SA Virani","year":"2016","unstructured":"Virani SA, Dent S, Brezden-Masley C et al (2016) <article-title update=\"added\">Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol 32(7):831\u2013841. https:\/\/doi.org\/10.1016\/j.cjca.2016.02.078","journal-title":"Can J Cardiol"},{"issue":"2","key":"10575_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M et al (2020) Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 31(2):171\u2013190. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.023","journal-title":"Ann Oncol"},{"issue":"42","key":"10575_CR32","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.3760\/cma.j.cn112137-20230908-00428","volume":"103","author":"Chinese Anti-Cancer Association Society of Integrative Cardio-oncology; Ultrasound Branch of the Chinese Medical Association","year":"2023","unstructured":"Chinese Anti-Cancer Association Society of Integrative Cardio-oncology; Ultrasound Branch of the Chinese Medical Association (2023) Chinese society of Echocardiography. [Chinese guideline for the clinical application of noninvasive imaging technology in accessing cancer therapy-related cardiovascular toxicity (2023 edition)]. Zhonghua Yi Xue Za Zhi 103(42):3367\u20133383. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20230908-00428","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"1","key":"10575_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40959-023-00159-0","volume":"9","author":"A Mir","year":"2023","unstructured":"Mir A, Badi Y, Bugazia S et al (2023) Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review and network meta-analysis. Cardiooncology 9(1):10. https:\/\/doi.org\/10.1186\/s40959-023-00159-0","journal-title":"Cardiooncology"},{"issue":"5","key":"10575_CR34","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jaccao.2024.07.010","volume":"6","author":"D Austin","year":"2024","unstructured":"Austin D, Maier RH, Akhter N et al (2024) Preventing cardiac damage in patients treated for breast cancer and lymphoma: the PROACT clinical trial. JACC CardioOncol 6(5):684\u2013696. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.010","journal-title":"JACC CardioOncol"},{"issue":"11","key":"10575_CR35","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1002\/cncr.21478","volume":"104","author":"H Nakamae","year":"2005","unstructured":"Nakamae H, Tsumura K, Terada Y et al (2005) Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104(11):2492\u20132498. https:\/\/doi.org\/10.1002\/cncr.21478","journal-title":"Cancer"},{"issue":"25","key":"10575_CR36","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","volume":"143","author":"SL Heck","year":"2021","unstructured":"Heck SL, Mecinaj A, Ree AH et al (2021) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2\u2009\u00d7\u20092 factorial, randomized, placebo-controlled, double-blind clinical trial of Candesartan and Metoprolol. Circulation 143(25):2431\u20132440. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054698","journal-title":"Circulation"},{"issue":"1","key":"10575_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-318","volume":"11","author":"E Pituskin","year":"2011","unstructured":"Pituskin E, Haykowsky M, Mackey JR et al (2011) <article-title update=\"added\">Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 11(1):318. https:\/\/doi.org\/10.1186\/1471-2407-11-318","journal-title":"BMC Cancer"},{"issue":"23","key":"10575_CR38","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left ventricular dysfunction with Enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hEmopathies). J Am Coll Cardiol 61(23):2355\u20132362. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.072","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10575_CR39","doi-asserted-by":"publisher","first-page":"102734","DOI":"10.1016\/j.cpcardiol.2024.102734","volume":"49","author":"A Avagimyan","year":"2024","unstructured":"Avagimyan A, Kajaia N, Gabunia L et al (2024) Place of beta-adrenergic receptor blockers in the treatment of arterial hypertension: from bench to bedside. Curr Probl Cardiol 49(10):102734. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102734","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"10575_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/CRD.0000000000000363","volume":"29","author":"L Boussi","year":"2021","unstructured":"Boussi L, Frishman WH (2021) \u03b2-arrestin is a therapeutic target in heart failure. Cardiol Rev 29(5):223\u2013229. https:\/\/doi.org\/10.1097\/CRD.0000000000000363","journal-title":"Cardiol Rev"},{"issue":"7","key":"10575_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14072247","volume":"14","author":"V Acerbo","year":"2025","unstructured":"Acerbo V, Cesaro A, Calabr\u00f2 P (2025) Do beta-blockers really matter in patients with myocardial infarction without left ventricular systolic dysfunction? A comment by Sabina et al. Beta-Blockers in patients with myocardial infarction and preserved left ventricular ejection: a systematic review and meta-analysis of randomized controlled trials. J Clin Med 14(7):2247. https:\/\/doi.org\/10.3390\/jcm14072247","journal-title":"J Clin Med"},{"key":"10575_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131544","volume":"395","author":"Y Li","year":"2024","unstructured":"Li Y, Yao S, Chen X (2024) Beneficial effects of beta-blockers in patients with myocardial infarction: what are the underlying mechanisms? Int J Cardiol 395:131544. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131544","journal-title":"Int J Cardiol"},{"issue":"5","key":"10575_CR43","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","volume":"21","author":"A Elitok","year":"2014","unstructured":"Elitok A, Oz F, Cizgici AY et al (2014) Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up. Cardiol J 21(5):509\u2013515. https:\/\/doi.org\/10.5603\/CJ.a2013.0150","journal-title":"Cardiol J"},{"issue":"20","key":"10575_CR44","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.048","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR et al (2018) Carvedilol for the prevention of Chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 71(20):2281\u20132290. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.048","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10575_CR45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.taap.2004.04.005","volume":"200","author":"PJ Oliveira","year":"2004","unstructured":"Oliveira PJ, Bjork JA, Santos MS et al (2004) Carvedilol-mediated antioxidant protection against DOX-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 200(2):159\u2013168. https:\/\/doi.org\/10.1016\/j.taap.2004.04.005","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10575_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(23)00637-X","volume":"25","author":"SH Armenian","year":"2024","unstructured":"Armenian SH, Hudson MM, Lindenfeld L et al (2024) Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomized, controlled, phase 2b trial. Lancet Oncol 25(2):235\u2013245. https:\/\/doi.org\/10.1016\/S1470-2045(23)00637-X","journal-title":"Lancet Oncol"},{"issue":"6","key":"10575_CR47","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10741-023-10328-z","volume":"28","author":"Y Gao","year":"2023","unstructured":"Gao Y, Wang R, Jiang J et al (2023) ACEI\/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis. Heart Fail Rev 28(6):1405\u20131415. https:\/\/doi.org\/10.1007\/s10741-023-10328-z","journal-title":"Heart Fail Rev"},{"issue":"21","key":"10575_CR48","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","volume":"148","author":"PA Henriksen","year":"2023","unstructured":"Henriksen PA, Hall P, MacPherson IR et al (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blocker and beta-blocker therapy to prevent anthracycline cardiotoxicity: the cardiac CARE trial. Circulation 148(21):1680\u20131690. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064274","journal-title":"Circulation"},{"issue":"3","key":"10575_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G et al (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to Pharmacological therapy. J Am Coll Cardiol 55(3):213\u2013220. https:\/\/doi.org\/10.1016\/j.jacc.2009.03.095","journal-title":"J Am Coll Cardiol"},{"key":"10575_CR50","doi-asserted-by":"publisher","first-page":"1537699","DOI":"10.3389\/fcdhc.2025.1537699","volume":"6","author":"A Avagimyan","year":"2025","unstructured":"Avagimyan A, Pogosova N, Rizzo M et al (2025) Doxorubicin-induced cardiometabolic disturbances: what can we do? Front Clin Diabetes Healthc 6:1537699. https:\/\/doi.org\/10.3389\/fcdhc.2025.1537699","journal-title":"Front Clin Diabetes Healthc"},{"issue":"16","key":"10575_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164772","volume":"13","author":"LN Roca","year":"2024","unstructured":"Roca LN, Garc\u00eda MC, Germ\u00e1n JB et al (2024) Use and benefit of Sacubitril\/Valsartan in elderly patients with heart failure with reduced ejection fraction. J Clin Med 13(16):4772. https:\/\/doi.org\/10.3390\/jcm13164772","journal-title":"J Clin Med"},{"issue":"3","key":"10575_CR52","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10741-025-10495-1","volume":"30","author":"A Mecinaj","year":"2025","unstructured":"Mecinaj A, Vinje-Jakobsen V, Ngo DTM et al (2025) SARAH trial: more evidence on the role of neurohormonal blockers in the prevention of anthracycline-induced cardiotoxicity. Heart Fail Rev 30(3):627\u2013631. https:\/\/doi.org\/10.1007\/s10741-025-10495-1","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10575_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40959-021-00115-w","volume":"7","author":"A Mecinaj","year":"2021","unstructured":"Mecinaj A, Gulati G, Heck SL et al (2021) Rationale and design of the prevention of cArdiac dysfunction during adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardiooncology 7(1):33. https:\/\/doi.org\/10.1186\/s40959-021-00115-w","journal-title":"Cardiooncology"},{"issue":"3","key":"10575_CR54","doi-asserted-by":"publisher","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","volume":"326","author":"S Verma","year":"2024","unstructured":"Verma S, Pandey A, Pandey AK et al (2024) Inhibitors of aldosterone and aldosterone synthase in cardiorenal diseases. Am J Physiol Heart Circ Physiol 326(3):H670\u2013H688. https:\/\/doi.org\/10.1152\/ajpheart.00419.2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10575_CR55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","volume":"17","author":"M Akpek","year":"2015","unstructured":"Akpek M, Ozdogru I, Sahin O et al (2015) Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 17(1):81\u201389. https:\/\/doi.org\/10.1002\/ejhf.196","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10575_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaccao.2019.10.001","volume":"1","author":"MK Davis","year":"2019","unstructured":"Davis MK, Villa D, Tsang TSM et al (2019) Effects of eplerenone on diastolic function in women receiving anthracycline-based chemotherapy for breast cancer. JACC: CardioOncology 1(2):295\u2013298. https:\/\/doi.org\/10.1016\/j.jaccao.2019.10.001","journal-title":"JACC: CardioOncology"},{"issue":"1","key":"10575_CR57","doi-asserted-by":"publisher","first-page":"e41629","DOI":"10.1016\/j.heliyon.2025.e41629","volume":"11","author":"Z Shi","year":"2025","unstructured":"Shi Z, Han S (2025) Personalized statin therapy: targeting metabolic processes to modulate the therapeutic and adverse effects of Statins. Heliyon 11(1):e41629. https:\/\/doi.org\/10.1016\/j.heliyon.2025.e41629","journal-title":"Heliyon"},{"issue":"1","key":"10575_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s43044-023-00327-8","volume":"75","author":"A Choudhary","year":"2023","unstructured":"Choudhary A, Rawat U, Kumar P et al (2023) <article-title update=\"added\">Pleotropic effects of statins: the dilemma of wider utilization of statin. Egypt Heart J 75(1):1. https:\/\/doi.org\/10.1186\/s43044-023-00327-8","journal-title":"Egypt Heart J"},{"issue":"1","key":"10575_CR59","doi-asserted-by":"publisher","first-page":"20298","DOI":"10.1038\/s41598-024-71240-6","volume":"14","author":"G Buccioli","year":"2024","unstructured":"Buccioli G, Testa C, Jacchetti E et al (2024) The molecular basis of the anticancer effect of Statins. Sci Rep 14(1):20298. https:\/\/doi.org\/10.1038\/s41598-024-71240-6","journal-title":"Sci Rep"},{"issue":"1","key":"10575_CR60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","volume":"40","author":"W Jiang","year":"2021","unstructured":"Jiang W, Hu JW, He XR et al (2021) Statins: A repurposed drug for cancer treatment. J Exp Clin Cancer Res 40(1):241. https:\/\/doi.org\/10.1186\/s13046-021-02041-2","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"10575_CR61","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","volume":"330","author":"TG Neilan","year":"2023","unstructured":"Neilan TG, Quinaglia T, Onoue T et al (2023) Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA 330(6):528\u2013536. https:\/\/doi.org\/10.1001\/jama.2023.11887","journal-title":"JAMA"},{"issue":"9","key":"10575_CR62","doi-asserted-by":"publisher","first-page":"EVIDoa2200097","DOI":"10.1056\/EVIDoa2200097","volume":"1","author":"WG Hundley","year":"2022","unstructured":"Hundley WG, D\u2019Agostino R, Crotts T et al (2022) Statins and left ventricular ejection fraction after doxorubicin treatment. NEJM Evid 1(9):EVIDoa2200097. https:\/\/doi.org\/10.1056\/EVIDoa2200097","journal-title":"NEJM Evid"},{"issue":"6","key":"10575_CR63","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","volume":"9","author":"P Thavendiranathan","year":"2023","unstructured":"Thavendiranathan P, Houbois C, Marwick TH et al (2023) Statins to prevent early cardiac dysfunction in cancer patients with increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother 9(6):515\u2013525. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad031","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"10575_CR64","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02426-1","volume":"41","author":"KM Kettana","year":"2024","unstructured":"Kettana KM, El-Haggar SM, Alm El-Din MA et al (2024) Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial. Med Oncol 41(8):196. https:\/\/doi.org\/10.1007\/s12032-024-02426-1","journal-title":"Med Oncol"},{"key":"10575_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131219","volume":"391","author":"D D'Amario","year":"2023","unstructured":"D\u2019Amario D, Laborante R, Bianchini E et al (2023) Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials. Int J Cardiol 391:131219. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131219","journal-title":"Int J Cardiol"},{"issue":"4","key":"10575_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60040580","volume":"60","author":"V Jaiswal","year":"2024","unstructured":"Jaiswal V, Ang SP, Deb N et al (2024) Association between statin use and chemotherapy-induced cardiotoxicity: a meta-analysis. Medicina (Kaunas) 60(4):580. https:\/\/doi.org\/10.3390\/medicina60040580","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"10575_CR67","doi-asserted-by":"publisher","first-page":"266","DOI":"10.20514\/2226-6704-2018-8-4-266-276","volume":"8","author":"AI Dyadyk","year":"2018","unstructured":"Dyadyk AI, Kugler TE, Suliman YV et al (2018) Statin adverse effects: mechanisms, diagnosis, prevention, and management. Russ Arch Intern Med 8(4):266\u2013276. https:\/\/doi.org\/10.20514\/2226-6704-2018-8-4-266-276","journal-title":"Russ Arch Intern Med"},{"issue":"21","key":"10575_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111687","volume":"22","author":"P Vinci","year":"2021","unstructured":"Vinci P, Panizon E, Tosoni LM et al (2021) Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci 22(21):11687. https:\/\/doi.org\/10.3390\/ijms222111687","journal-title":"Int J Mol Sci"},{"key":"10575_CR69","doi-asserted-by":"publisher","first-page":"89","DOI":"10.15829\/1560-4071-2018-9-89-99","volume":"9","author":"Zh Kobalava","year":"2018","unstructured":"Kobalava Zh, Lazarev P, Villevalde S (2018) Statins associated diabetes: state of the problem in 2018. Russ J Cardiol 9:89\u201399. https:\/\/doi.org\/10.15829\/1560-4071-2018-9-89-99","journal-title":"Russ J Cardiol"},{"key":"10575_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116794","volume":"482","author":"L Chen","year":"2024","unstructured":"Chen L, Sun X, Wang Z et al (2024) Resveratrol protects against doxorubicin-induced cardiotoxicity by attenuating ferroptosis through modulating the MAPK signaling pathway. Toxicol Appl Pharmacol 482:116794. https:\/\/doi.org\/10.1016\/j.taap.2023.116794","journal-title":"Toxicol Appl Pharmacol"},{"key":"10575_CR71","doi-asserted-by":"publisher","first-page":"1289384","DOI":"10.3389\/fcvm.2023.1289384","volume":"10","author":"A Faggiano","year":"2023","unstructured":"Faggiano A, Gherbesi E, Avagimyan A et al (2023) Melatonin mitigates oxidative damage induced by anthracycline: a systematic-review and meta-analysis of murine models. Front Cardiovasc Med 10:1289384. https:\/\/doi.org\/10.3389\/fcvm.2023.1289384","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10575_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27164","volume":"10","author":"AA Shati","year":"2024","unstructured":"Shati AA, Eid RA, El-Kott AF et al (2024) Curcumin attenuates doxorubicin-induced cardiotoxicity via suppressing oxidative stress, preventing inflammation and apoptosis: ultrastructural and computational approaches. Heliyon 10(5):e27164. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27164","journal-title":"Heliyon"},{"key":"10575_CR73","doi-asserted-by":"publisher","first-page":"960327123119862","DOI":"10.1177\/09603271231198624","volume":"42","author":"RM Elmorsi","year":"2023","unstructured":"Elmorsi RM, Kabel AM, El Saadany AA et al (2023) Protective effects of topiramate and spirulina against DOX-induced cardiotoxicity in rats. Hum Exp Toxicol 42:9603271231198624. https:\/\/doi.org\/10.1177\/09603271231198624","journal-title":"Hum Exp Toxicol"},{"key":"10575_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116405","volume":"461","author":"A Elfadadny","year":"2023","unstructured":"Elfadadny A, Ragab RF, Hamada R et al (2023) Natural bioactive compound\u2013doxorubicin combinations targeting topoisomerase II-alpha: anticancer efficacy and safety. Toxicol Appl Pharmacol 461:116405. https:\/\/doi.org\/10.1016\/j.taap.2023.116405","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10575_CR75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00395-024-01080-y","volume":"120","author":"AE Vi\u00f1as-Mendieta","year":"2025","unstructured":"Vi\u00f1as-Mendieta AE, Gallardo-Grajeda A, L\u00f3pez-Fern\u00e1ndez T (2025) Cardio-oncology: opportunities and challenges. Basic Res Cardiol 120(1):3\u20139. https:\/\/doi.org\/10.1007\/s00395-024-01080-y","journal-title":"Basic Res Cardiol"},{"issue":"2","key":"10575_CR76","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jaccao.2024.02.004","volume":"6","author":"JN Upshaw","year":"2024","unstructured":"Upshaw JN, Parson SK, Buchsbaum RJ et al (2024) Dexrazoxane to prevent cardiotoxicity in adults treated with anthracyclines: JACC: Cardio-oncology controversies in cardio-oncology. JACC CardioOncol 6(2):322\u2013324. https:\/\/doi.org\/10.1016\/j.jaccao.2024.02.004","journal-title":"JACC CardioOncol"},{"issue":"9","key":"10575_CR77","doi-asserted-by":"publisher","first-page":"CD014638","DOI":"10.1002\/14651858.CD014638.pub2","volume":"9","author":"EC de Baat","year":"2022","unstructured":"de Baat EC, Mulder RL, Armenian S et al (2022) Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracycline. Cochrane Database Syst Rev 9(9):CD014638. https:\/\/doi.org\/10.1002\/14651858.CD014638.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10575_CR78","doi-asserted-by":"publisher","first-page":"e37308","DOI":"10.7759\/cureus.37308","volume":"15","author":"P Rahimi","year":"2023","unstructured":"Rahimi P, Barootkoob B, Elhasha A et al (2023) Efficacy of dexrazoxane in cardiac protection in pediatric patients treated with anthracyclines. Cureus 15(4):e37308. https:\/\/doi.org\/10.7759\/cureus.37308","journal-title":"Cureus"},{"issue":"1","key":"10575_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-025-00323-8","volume":"11","author":"H Zheng","year":"2025","unstructured":"Zheng H, Zhan H (2025) Dexrazoxane makes doxorubicin-induced heart failure a rare event in patients with sarcoma receiving high cumulative doses. Cardiooncology 11(1):29. https:\/\/doi.org\/10.1186\/s40959-025-00323-8","journal-title":"Cardiooncology"},{"issue":"11","key":"10575_CR80","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.3390\/jcm13113352","volume":"13","author":"F Guerra","year":"2024","unstructured":"Guerra F, Stronati G, Frangione A et al (2024) Pattern in patients treated with anthracyclines or Anti-HER2. J Clin Med 13(11):3352. https:\/\/doi.org\/10.3390\/jcm13113352","journal-title":"J Clin Med"},{"issue":"14","key":"10575_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144795","volume":"12","author":"V Bucciarelli","year":"2023","unstructured":"Bucciarelli V, Bianco F, Di Blasio A et al (2023) Cardiometabolic profile, physical activity, and quality of life in breast cancer survivors after different physical exercise protocols: a 34-month follow-up study. J Clin Med 12(14):4795. https:\/\/doi.org\/10.3390\/jcm12144795","journal-title":"J Clin Med"},{"issue":"22","key":"10575_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226745","volume":"11","author":"L Fazzini","year":"2022","unstructured":"Fazzini L, Caggiari L, Deidda M et al (2022) Metabolomic profiles on antiblastic cardiotoxicity: new perspectives for early diagnosis and cardioprotection. J Clin Med 11(22):6745. https:\/\/doi.org\/10.3390\/jcm11226745","journal-title":"J Clin Med"},{"issue":"1 Pt C","key":"10575_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.102187","volume":"49","author":"S Khaled","year":"2024","unstructured":"Khaled S, Abdelkhalek S, Aljuwaybiri R et al (2024) Cardiac dysfunction and their determinants in patients treated for breast cancer and lymphoma: a cardio-oncology center experience. Curr Probl Cardiol 49(1 Pt C):102187. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102187","journal-title":"Curr Probl Cardiol"},{"key":"10575_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2024.107683","volume":"73","author":"A Avagimyan","year":"2024","unstructured":"Avagimyan A, Pogosova N, Kakturskiy L et al (2024) Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury. Cardiovasc Pathol 73:107683. https:\/\/doi.org\/10.1016\/j.carpath.2024.107683","journal-title":"Cardiovasc Pathol"},{"issue":"15","key":"10575_CR85","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.2174\/0109298673320425240806051215","volume":"32","author":"M Rahimifard","year":"2025","unstructured":"Rahimifard M, Baeeri M, Haghi-Aminjan H et al (2025) Unveiling the protective role of metformin against chemotherapy-induced cardiotoxicity: a comprehensive scoping review on non-clinical studies. Curr Med Chem 32(15):3069\u20133087. https:\/\/doi.org\/10.2174\/0109298673320425240806051215","journal-title":"Curr Med Chem"},{"key":"10575_CR86","doi-asserted-by":"publisher","unstructured":"Avagimyan A, Sheibani M, Trofimenko A et al (2024) Protective potential of Sodium-Glucose cotransporter 2 inhibitors in internal medicine (Part 1). Innov Med Kuban 4126\u2013135. https:\/\/doi.org\/10.35401\/2541-9897-2024-9-4-126-135","DOI":"10.35401\/2541-9897-2024-9-4-126-135"},{"issue":"1","key":"10575_CR87","doi-asserted-by":"publisher","first-page":"101","DOI":"10.35401\/2541-9897-2025-10-1-101-109","volume":"10","author":"A Avagimyan","year":"2025","unstructured":"Avagimyan A, Sheibani M, Trofimenko A et al (2025) Protective potential of sodium-glucose cotransporter 2 inhibitors in internal medicine (Part 2). Innov Med Kuban 10(1):101\u2013109. https:\/\/doi.org\/10.35401\/2541-9897-2025-10-1-101-109","journal-title":"Innov Med Kuban"},{"issue":"8","key":"10575_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082705","volume":"14","author":"F Biondi","year":"2025","unstructured":"Biondi F, Madonna R (2025) Potential role of GLP1-RAs against anticancer-drug cardiotoxicity: a scoping review. J Clin Med 14(8):2705. https:\/\/doi.org\/10.3390\/jcm14082705","journal-title":"J Clin Med"},{"issue":"7","key":"10575_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2025.103073","volume":"50","author":"P Karakasis","year":"2025","unstructured":"Karakasis P (2025) Blind spot in cardiotoxicity: reassessment of right ventricular dysfunction in the era of SGLT2 inhibitors. Curr Probl Cardiol 50(7):103073. https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103073","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"10575_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102882","volume":"50","author":"A Avagimyan","year":"2025","unstructured":"Avagimyan A, Kakturskiy L, Pogosova N et al (2025) Doxorubicin and cyclophosphamide mode of chemotherapy-related cardiomyopathy: review of preclinical model. Curr Probl Cardiol 50(1):102882. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102882","journal-title":"Curr Probl Cardiol"},{"key":"10575_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131331","volume":"391","author":"A Avagimyan","year":"2023","unstructured":"Avagimyan A, Sheibani M, Pogosova N et al (2023) Possibilities of dapagliflozin-induced cardioprotection on doxorubicin\u2009+\u2009cyclophosphamide mode of chemotherapy-induced cardiomyopathy. Int J Cardiol 391:131331. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131331","journal-title":"Int J Cardiol"},{"issue":"17","key":"10575_CR92","doi-asserted-by":"publisher","first-page":"10146","DOI":"10.3390\/ijms231710146","volume":"23","author":"PL Hsieh","year":"2022","unstructured":"Hsieh PL, Chu PM, Cheng HC et al (2022) Dapagliflozin mitigates DOX-induced myocardial damage by regulating AKT-mediated oxidative stress, cardiac Remodeling, and inflammation. Int J Mol Sci 23(17):10146. https:\/\/doi.org\/10.3390\/ijms231710146","journal-title":"Int J Mol Sci"},{"key":"10575_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117278","volume":"178","author":"L Mattii","year":"2024","unstructured":"Mattii L, Moscato S, Ippolito C et al (2024) Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway. Biomed Pharmacother 178:117278. https:\/\/doi.org\/10.1016\/j.biopha.2024.117278","journal-title":"Biomed Pharmacother"},{"key":"10575_CR94","doi-asserted-by":"publisher","first-page":"1289663","DOI":"10.3389\/fcvm.2024.1289663","volume":"11","author":"V Quagliariello","year":"2024","unstructured":"Quagliariello V, Canale ML, Bisceglia I et al (2024) Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-\u03baB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity. Front Cardiovasc Med 11:1289663. https:\/\/doi.org\/10.3389\/fcvm.2024.1289663","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10575_CR95","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/toxres\/tfad007","volume":"12","author":"M Chen","year":"2023","unstructured":"Chen M (2023) Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK\/SIRT-1\/PGC-1\u03b1-mediated mitochondrial biogenesis. Toxicol Res (Camb) 12(2):216\u2013223. https:\/\/doi.org\/10.1093\/toxres\/tfad007","journal-title":"Toxicol Res (Camb)"},{"key":"10575_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2023.107171","volume":"150","author":"A Faggiano","year":"2023","unstructured":"Faggiano A, Gherbesi E, Cardinale D et al (2023) SGLT2-i prevent left ventricular dysfunction induced by anthracycline in mouse model: a systematic-review and meta-analysis. Vasc Pharmacol 150:107171. https:\/\/doi.org\/10.1016\/j.vph.2023.107171","journal-title":"Vasc Pharmacol"},{"key":"10575_CR97","doi-asserted-by":"publisher","unstructured":"Bhalraam U, Veerni RB, Paddock S et al (2025) Impact of sodium-glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis. Eur J Prev Cardiol zwaf026. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf026","DOI":"10.1093\/eurjpc\/zwaf026"},{"issue":"10","key":"10575_CR98","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s11912-024-01577-8\/","volume":"26","author":"N Osataphan","year":"2024","unstructured":"Osataphan N, Abdel-Qadir H, Zebrowska AM et al (2024) Sodium-Glucose cotransporter 2 inhibitors during cancer therapy: Benefits, Risks, and ongoing clinical trials. Curr Oncol Rep 26(10):1188\u20131196. https:\/\/doi.org\/10.1007\/s11912-024-01577-8\/","journal-title":"Curr Oncol Rep"},{"key":"10575_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2025.107526","volume":"160","author":"A Avagimyan","year":"2025","unstructured":"Avagimyan A, Madonna R, Sheibani M et al (2025) Translational aspects of doxorubicin-induced cardiotoxicity: what we have omitted for the past decades? Vascul Pharmacol 160:107526. https:\/\/doi.org\/10.1016\/j.vph.2025.107526","journal-title":"Vascul Pharmacol"},{"key":"10575_CR100","doi-asserted-by":"publisher","unstructured":"Cautela J, Alexandre J (2025) SGLT2 inhibitors in cancer patients: A paradigm shift in Cardio-Oncology? Eur J Prev Cardiol zwaf146. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf146","DOI":"10.1093\/eurjpc\/zwaf146"}],"updated-by":[{"DOI":"10.1007\/s10741-025-10590-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000}}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10575-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10575-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10575-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T20:02:39Z","timestamp":1768939359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10575-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10575"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10575-2","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this paper was updated to correct the author's family name from \"Madona\" to \"Madonna\"","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10741-025-10590-3","URL":"https:\/\/doi.org\/10.1007\/s10741-025-10590-3","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ashot Avagimyan, the first author of this submission, is part of his Dissertation for Doctor of Science (DSc) in Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Compliance"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}